Theravance Biopharma to Present New COPD Data at CHEST 2025 Meeting

Theravance Biopharma will present new analyses on YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting. A retrospective cohort study showed that adherent patients had significantly fewer and less severe exacerbations, and lower healthcare costs than non-adherent patients. Post-hoc analyses of a Phase 3 safety study showed that YUPELRI patients had significantly lower incidence of moderate-to-severe acute exacerbations and overall less severe exacerbations than tiotropium patients.